Total Funding
73
63
Total FundingGrant raised
Growth Score
-3 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
101931
Allogenica develops allogenic CAR-T cells using donor stem cells for cancer treatment.
- Inna Menkova: CEO & Co-founderPast Role: Léon Bérard Center, Project Leader - Start-Up co-Founder
Tobias Abel: CSO
About the Company
Allogenica specializes in biotechnology, focusing on the development of allogenic CAR-T cells. These cells are derived from healthy donor hematopoietic stem cells and are bioengineered to express Chimeric Antigen Receptors (CAR) for cancer treatment. This approach aims to provide universal cancer therapies that can be administered to patients
without the need for individualized cell harvesting and engineering.
